N/A
Completed N=2,974
A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
Source: ClinicalTrials.gov NCT01354990 ↗Enrolled (actual)
2,974
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcomePrimary: Number of Participants With an Adverse Event — 25 participants
Summary
The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With an Adverse Event |
25 | — |
| PRIMARY Age of Participants Prescribed Sitagliptin |
55 | — |
| PRIMARY Number of Participants With Concomitant Therapies |
1878 | — |
| PRIMARY Number of Participants With Concomitant Conditions |
752 | — |
Eligibility Criteria
Inclusion Criteria
- Must be taking sitagliptin (JANUVIA™) for the treatment of type 2 diabetes
mellitus
- Treating physician must agree to provide information regarding the participants treatment
Data sourced from ClinicalTrials.gov (NCT01354990). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.